A recent congressional hearing on 340B is the latest iteration of a standoff between two pillars of the healthcare industry—hospitals and pharmaceutical manufacturers—both of which have powerful ...
There's a backdoor effort gaining momentum in states across the country that allows taxpayer-subsidized funding for "sex change" procedures to be performed on pediatric patients. 340B, a cost-saving ...
Four drug manufacturers have announced plans to offer discounted drug prices to safety net providers under the federal 340B program via rebates instead of upfront discounts, despite the federal ...
The share of Medicare Part D claims eligible for discounts in the 340B drug pricing program increased from 1.7 percent to 9.6 percent between 2013 and 2020, a study published in JAMA Health Forum ...
The 340B Drug Pricing Program is a federal program in which participating hospitals and clinics are able to purchase qualifying drugs from pharmaceutical manufacturers at Medicaid-like pricing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results